The purpose of this retrospective study was to identify ovarian, breast, prostate and pancreatic cancer patients who may have additional mutations and were previously only tested for BRCA1 and BRCA2 but may benefit from PARPi. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.